noul said on the 15th that it signed a contract to supply its blood analysis products to Romania.
Under this contract, noul will supply the new artificial intelligence (AI)-based blood analysis solution "miLab BCM," which integrates complete blood count (CBC) functionality, and the malaria diagnostic solution "miLab MAL" to major hospitals and diagnostic institutions in Romania.
miLab BCM is an all-in-one blood analysis platform that applies AI-based image cytometry technology. With only a small amount of whole blood of 5 μL (microliter; 1 μL is 1/1,000,000 of a liter), it can perform not only CBC tests but also screening and abnormal cell detection.
In recent performance verification conducted with Asan Medical Center, it detected immature granulocytes (IG) and blasts, which are difficult to detect with existing equipment, with high accuracy, and secured reliability in morphology-based abnormal cell analysis beyond simple numerical measurements.
This contract follows a supply agreement for a cervical cancer diagnostic solution covering six Eastern European countries. Through this, noul has established a foundation to sell all three currently launched product lines in Eastern Europe.
Romania is a market where demand for CBC tests and test automation infrastructure are rapidly expanding within Europe, with the introduction of automated hematology analyzers increasing, centered on public hospitals and large private testing centers.
noul recently signed a miLab rental contract with Germany's largest diagnostic lab chain, expanding its presence into the Western European market. Early this month, it also clinched a supply contract in Slovenia, continuing its momentum in Europe.
The company plans to target markets in countries with advanced medical environments with the new miLab BCM equipped with CBC functionality, aiming to build long-term growth potential and a stable revenue base.
Chief Executive Lim Chan-yang of noul said, "Eastern European countries, including Romania, are key footholds for entry into Europe," adding, "Based on a differentiated business model and market access strategy, we are successively closing supply contracts, and next year we plan to accelerate market expansion to neighboring countries and across Europe."